Recommendations For Better Patient Outcomes in LDL-C Management

This EMJ podcast explores the vital topic of low-density lipoprotein cholesterol (LDL-C) management in relation to the treatment and prevention of atherosclerotic cardiovascular disease. Our host, George Cooper, is joined by Michal Vrablík, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Vrablík provides a basic overview of LDL-C, how it might lead to atherosclerotic cardiovascular disease, and how this can ultimately cause a myocardial infarction. Vrablík covers current treatments for patients with high LDL-C, including statins, ezetimibe, and monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin Type 9.

Disclaimer: This independent medical education activity is provided by EMJ, and was supported by independent funding from Novartis Pharma AG, who have had no input into the content.  This educational activity is intended for an audience of non-US healthcare professionals. These materials may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.